Clinical trials: Leukopenia
Myelokathexis, Infections
Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome
Background: WHIMS (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome) is a rare disease. It can cause cancers, infections, and warts. Researchers want to see if a drug called plerixafor can treat WHIMS.
- Conditions
- Myelokathexis, Infections, Neutropenia, Warts
- Trial name
- NCT02231879
- Testing
- Plerixafor, G-CSF
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cancer Pediatric, Neutropenia
Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
This study aims to demonstrate the safety of intracutaneous needles in pediatric cancer patients. For this, a two-year retrospective study will be carried out to determine the incidence of adverse effects related to acupuncture…
- Conditions
- Cancer Pediatric, Neutropenia, Thrombocytopenia, Bacteremia
- Trial name
- ACUSAFE2021 (NCT05585463)
- Testing
- acupuncture
- Where
- Spain
- Volunteers
- 460 people
- Sponsor
- Fundació Sant Joan de Déu
X-Linked Agammaglobulinemia, X-Linked Hyper IgM Syndrome
Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders
OBJECTIVES: I. Identify the molecular defects responsible for primary immunodeficiency disorders. II. Explore the mutations within each syndrome to better understand the genetics of these disorders. III.
- Conditions
- X-Linked Agammaglobulinemia, X-Linked Hyper IgM Syndrome, Wiskott-Aldrich Syndrome, Leukocyte Adhesion Deficiency Syndrome
- Trial name
- NCT00004341
- Where
- United States
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Febrile Neutropenia
Efficacy of Oral Supplementation With Magnesium to Reduce Febrile Neutropenia
Clinical Trial. Open label. Parallel Groups. The purpose of the study is to determine the efficacy of oral supplementation with magnesium oxide to reduce febrile neutropenia episodes in pediatric oncology patients treated with…
- Trial name
- NCT03449693
- Testing
- Magnesium Oxide Supplement
- Where
- Mexico
- Volunteers
- 214 people
- Sponsor
- Universidad Nacional Autonoma de Mexico
Neutropenia, Febrile
Antibiotics Management of Septic Neutropenic Patients in the Intensive Care Unit
Neutropenia, defined by an absolute count of polymorphonuclear neutrophils less than <1500/mm3, exposes patients to infectious complications that can lead to sepsis or septic shock. The mortality risk is higher risk.
- Trial name
- REANEUF (NCT03217721)
- Where
- France
- Volunteers
- 130 people
- Sponsor
- University Hospital, Brest
Pediatric Cancer, Febrile Neutropenia
Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy
In this pilot study the feasibility of continous monitoring of health data with a small, on-skin wearable device (the Everion®, by Biovotion, Zurich) in pediatric patients under chemotherapy for cancer, is studied.
- Conditions
- Pediatric Cancer, Febrile Neutropenia, Chemotherapy-induced Neutropenia, Oncology
- Trial name
- NCT04134429
- Testing
- Everion
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Leukemia, Neutropenia
Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00002658
- Testing
- filgrastim, amsacrine, cyclophosphamide
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Medical Research Council
Neutropenia, Agranulocytosis
Natural History Study for BEN
In recent decades, hematologists have noticed that persons of African descent sometimes have lower white blood cell counts of a certain type, called granulocytes. These cells help to fight infections.
- Conditions
- Neutropenia, Agranulocytosis, Hematologic Diseases, Leukocyte Disorders
- Trial name
- NCT00059423
- Where
- United States
- Volunteers
- 178 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Neutropenia, Hematopoietic Stem Cell Transplantation
Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation
Neutropenia is very common in patients received hematopoietic stem cell transplantation, with median duration of about 14 days. Almost all neutropenia will suffer from febrile without prophylactic antibiotics.
- Trial name
- NCT01714557
- Testing
- Piperacillin, Piperacillin-tazobactam combination product
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Chinese PLA General Hospital
Fever, Mycoses
Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia
The objective of this study is to evaluate the safety, tolerance, and pharmacokinetics of FK463, a novel echinocandin (cell wall-active antifungal lipopeptide), as early empirical therapy for prevention of fungal infections in…
- Conditions
- Fever, Mycoses, Neutropenia
- Trial name
- NCT00001790
- Testing
- FK463
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Neutropenia
International Registry for Severe Chronic Neutropenia
OBJECTIVES: I. Document the clinical course of severe chronic neutropenia (SCN). II. Monitor and assess long term safety of primary treatment in SCN patients in the United States, Canada, Europe, and Australia. III.
- Trial name
- NCT00004342
- Where
- 10 sites in United States, Australia and 3 more
- Volunteers
- 1,000 people
- Sponsor
- National Center for Research Resources (NCRR)
Wiskott-Aldrich Syndrome
Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS)
Wiskott-Aldrich syndrome (WAS) is a rare X-linked congenital immune-deficiency syndrome and hematopoietic stem cell transplantation (HSCT) has become a curative modality.
- Trial name
- NCT00885833
- Testing
- Fludarabine, Busulfan, Thymoglobulin
- Where
- South Korea
- Volunteers
- 5 people
- Sponsor
- The Korean Society of Pediatric Hematology Oncology
CD4 Lymphocytopenia, Idiopathic CD4 Positive T Lymphocytopenia
Evaluation of HIV-Negative Patients With Low CD4+ T Lymphocyte Counts
This study will evaluate HIV-negative patients with unusually low levels of CD4+ T lymphocytes (a type of white blood cell) to learn more about the clinical symptoms, cause, immunology, and biology of this problem.
- Trial name
- NCT00001319
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Stem Cell Transplantation, Bone Marrow Transplantation
Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells
Many genetic diseases of lymphohematopoietic cells (such as sickle cell anemia, thalassemia, Diamond-Blackfan anemia, Combined Immune Deficiency (CID), Wiskott-Aldrich syndrome, chronic granulomatous disease, X-linked…
- Conditions
- Stem Cell Transplantation, Bone Marrow Transplantation, Peripheral Blood Stem Cell Transplantation, Allogeneic Transplantation
- Trial name
- NCT02512679
- Testing
- Cyclophosphamide Dose Level 1, Cyclophosphamide Dose Level 2, Cyclophosphamide Dose Level 3
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Los Angeles
Sepsis (SMQ), Opportunistic Infections
Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related Toxicities
Although antibody-drug conjugate(ADC) has proved effective in treating many cancers, few patients receiving ADC may experience rare but life-threatening sepsis-related toxicities such as sepsis and septic shock.
- Conditions
- Sepsis (SMQ), Opportunistic Infections, Agranulocytosis
- Trial name
- NCT05349383
- Testing
- Antibody-Drug Conjugate, Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate
- Where
- China
- Volunteers
- 24,618 people
- Sponsor
- Central South University
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
This phase II trial studies how well giving fludarabine phosphate, melphalan, and low-dose total-body irradiation (TBI) followed by donor peripheral blood stem cell transplant (PBSCT) works in treating patients with hematologic…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01529827
- Testing
- fludarabine phosphate, melphalan, total-body irradiation
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Roswell Park Cancer Institute
Acquired Immunodeficiency Syndrome, Aspergillosis
Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis
Invasive aspergillosis is a fungal disease which is increasing in incidence with the increase in immunocompromised persons in our population.
- Conditions
- Acquired Immunodeficiency Syndrome, Aspergillosis, HIV Infections, Immunologic Deficiency Syndromes
- Trial name
- NCT00001646
- Testing
- Voriconazole, Amphotericin B
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Mycoses, HIV Infections
A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal Infections
To compare the safety, tolerance and efficacy of fluconazole and amphotericin B as treatment for biopsy proven fungal infections in major organs, disseminated infection, suspected fungal infection and fungemia in adult…
- Trial name
- NCT00002277
- Testing
- Fluconazole, Amphotericin B
- Where
- 3 sites in United States
- Sponsor
- Pfizer
Wiskott-Aldrich Syndrome
Post-transplant Cyclophosphamide in Wiskott-Aldrich Syndrome
A protocol named as "CIP-2015" for patients with Wiskott-Aldrich Syndrome may reduce the rate of GvHD. The details of the protocal followed with: 1. Conditioning regimen Busulfan 16 mg/kg in total, Fludarabine 160 mg/m2 in total.
- Trial name
- NCT03198195
- Testing
- cyclophosphamide
- Volunteers
- 5 people
- Sponsor
- Capital Research Institute of Pediatrics
SCID, Omenn's Syndrome
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
This is a standard of care treatment guideline for allogeneic hematopoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.
- Conditions
- SCID, Omenn's Syndrome, Reticular Dysgenesis, Wiskott-Aldrich Syndrome
- Trial name
- NCT01652092
- Testing
- Alemtuzumab 0.3 mg, Cyclophosphamide, Busulfan
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Masonic Cancer Center, University of Minnesota